Aethlon Medical, Inc. (AEMD): Price and Financial Metrics


Aethlon Medical, Inc. (AEMD): $1.17

0.11 (+10.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AEMD POWR Grades


  • AEMD scores best on the Sentiment dimension, with a Sentiment rank ahead of 95.64% of US stocks.
  • AEMD's strongest trending metric is Growth; it's been moving up over the last 117 days.
  • AEMD ranks lowest in Stability; there it ranks in the 7th percentile.

AEMD Stock Summary

  • Aethlon Medical Inc's market capitalization of $22,650,100 is ahead of only 3.9% of US-listed equities.
  • AEMD's price/sales ratio is 71.84; that's higher than the P/S ratio of 97.02% of US stocks.
  • Revenue growth over the past 12 months for Aethlon Medical Inc comes in at -62.09%, a number that bests only 2.39% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Aethlon Medical Inc, a group of peers worth examining would be CVLG, MLP, GRWG, PSB, and MEC.
  • AEMD's SEC filings can be seen here. And to visit Aethlon Medical Inc's official web site, go to www.aethlonmedical.com.

AEMD Valuation Summary

  • In comparison to the median Healthcare stock, AEMD's price/sales ratio is 537% higher, now standing at 72.3.
  • Over the past 75 months, AEMD's price/earnings ratio has gone up 3.3.
  • AEMD's EV/EBIT ratio has moved up 6.9 over the prior 75 months.

Below are key valuation metrics over time for AEMD.

Stock Date P/S P/B P/E EV/EBIT
AEMD 2021-08-31 72.3 2.3 -6.7 -3.7
AEMD 2021-08-30 70.7 2.2 -6.5 -3.6
AEMD 2021-08-27 77.4 2.5 -7.1 -4.2
AEMD 2021-08-26 70.4 2.2 -6.5 -3.6
AEMD 2021-08-25 70.0 2.2 -6.5 -3.5
AEMD 2021-08-24 66.9 2.1 -6.2 -3.2

AEMD Growth Metrics

    Its 5 year revenue growth rate is now at -26.66%.
  • Its 5 year price growth rate is now at -97.34%.
  • Its 5 year cash and equivalents growth rate is now at 352.83%.
Over the past 15 months, AEMD's revenue has gone down $304,905.

The table below shows AEMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.315282 -8.90671 -8.893984
2021-09-30 0.923036 -8.386 -8.811144
2021-06-30 0.79107 -7.734795 -8.573729
2021-03-31 0.659104 -6.76494 -7.886709
2020-12-31 0.8316 -6.146664 -7.406645
2020-09-30 0.620187 -5.205643 -5.783334

AEMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AEMD has a Quality Grade of D, ranking ahead of 11.25% of graded US stocks.
  • AEMD's asset turnover comes in at 0.049 -- ranking 72nd of 75 Measuring and Control Equipment stocks.
  • FCUV, SYPR, and SENS are the stocks whose asset turnover ratios are most correlated with AEMD.

The table below shows AEMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.049 1 11.337
2021-03-31 0.048 1 10.363
2020-12-31 0.061 1 11.087
2020-09-30 0.053 1 11.287
2020-06-30 0.076 1 13.238
2020-03-31 0.135 1 15.993

AEMD Price Target

For more insight on analysts targets of AEMD, see our AEMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.33 Average Broker Recommendation 1.5 (Moderate Buy)

AEMD Stock Price Chart Interactive Chart >

Price chart for AEMD

AEMD Price/Volume Stats

Current price $1.17 52-week high $6.22
Prev. close $1.06 52-week low $0.88
Day low $1.08 Volume 392,800
Day high $1.18 Avg. volume 223,053
50-day MA $1.13 Dividend yield N/A
200-day MA $1.99 Market Cap 18.03M

Aethlon Medical, Inc. (AEMD) Company Bio


Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.


AEMD Latest News Stream


Event/Time News Detail
Loading, please wait...

AEMD Latest Social Stream


Loading social stream, please wait...

View Full AEMD Social Stream

Latest AEMD News From Around the Web

Below are the latest news stories about Aethlon Medical Inc that investors may wish to consider to help them evaluate AEMD as an investment opportunity.

AEMD: Positive Takeaways from Plan to Expand Clinical Efforts

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Several medical centers actively screening patients for enrollment Aethlon Medical (NASDAQ:AEMD) hosted a call and provided a business update yesterday. The company’s lead product is the Hemopurifier®, an extracorporeal (i.e. outside of the body) blood filtration device that is designed to selectively remove harmful particles from the

Yahoo | February 15, 2022

Aethlon Medical''s (AEMD) CEO Chuck Fisher on Q3 2022 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 14, 2022

Aethlon Medical GAAP EPS of -$0.16 misses by $0.02, revenue of $0.02M misses by $0.19M

Aethlon Medical press release (NASDAQ:AEMD): FQ3 GAAP EPS of -$0.16 misses by $0.02.Revenue of $0.02M (-96.8% Y/Y) misses by $0.19M.

Seeking Alpha | February 14, 2022

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2021 and provided an update on recent developments.

Yahoo | February 14, 2022

Aethlon Medical Q3 2022 Earnings Preview (NASDAQ:AEMD)

Aethlon Medical (NASDAQ:AEMD) is scheduled to announce Q3 earnings results on Monday, February 14th, after market close.The consensus EPS Estimate is -$0.14 (+30.0% Y/Y) and the

Seeking Alpha | February 11, 2022

Read More 'AEMD' Stories Here

AEMD Price Returns

1-mo N/A
3-mo -19.86%
6-mo -37.10%
1-year -77.01%
3-year -78.63%
5-year -96.36%
YTD -37.10%
2021 -24.70%
2020 156.49%
2019 -96.13%
2018 46.90%
2017 -73.10%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5722 seconds.